The Role of CVP and EF in Patients With Cardio-renal Syndromes

Some Characteristics of Interaction Between Heart and Kidneys in Cardio-Renal Syndrome Type 1 and Type 2

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02792387

Acronym

RoCVPinCRSs

Enrollment

Registered

2016-06-07

Start date

2015-09-30

Completion date

2017-01-31

Last updated

2017-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

cardio-renal syndrome, right heart dysfunction, central venous pressure, eGFR, low-flow theory

Brief summary

The aim of the study is to explore association between increased central venous pressure, Ejection Fraction and renal dysfunction (eGFR) in patients with Cardio-Renal Syndromes type 1 and 2. The pilot study was set to provide the expected correlation coefficient for a sample size determination of the subsequent study.

Detailed description

OBJECTIVES The aim of the study is to explore association between increased central venous pressure (CVP), Ejection Fraction (EF) and renal dysfunction (eGFR) in patients with Cardio-Renal Syndromes type 1 and 2. BACKGROUND The pathophysiology of impaired renal function in cardiovascular disease is multifactorial. Recent investigations suggest that management of patients based on low-flow theory does not lead to improved outcomes. Relative importance of right heart dysfunction (manifested as increased CVP) has not been evaluated . Precise understanding of bidirectional pathways by which the heart and kidneys influence each other is necessary to define optimal treatment strategies specific to the subtypes, as therapies directed towards one organ system may have beneficial or unfavorable effects on the other. METHODS The study is of non-experimental (observational) type, based on retrospective chart review. The patients' personal identifiers are concealed and an anonymized datasets used (unique code given to each patient, which is kept secure under the control of hospital staff).

Interventions

OTHERCVP measurement

CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* HF (NYHA class I - IV, with preserved and reduced EF) and reduced GFR (Cardio-Renal Syndromes 1 and 2)

Exclusion criteria

* Independent risk factors for renal impairment (e.g. diabetes, sepsis) * Primary nephropathy or secondary nephropathy due to diseases other than HF

Design outcomes

Primary

Measure	Time frame	Description
renal impairment (defined as a Glomerular Filtration Rate less than 60 mL/min per 1.73 m2)	through study completion, an average of 1 year	Estimated Glomerular Filtration Rate has been assessed with the Modification of Diet in Renal Disease formula

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026